The heart failure epidemic is growing and its prevention, in order to reduce associated
hospital readmission rates and its clinical and economic burden, is a key issue in modern …

Background Diabetes and elevated blood glucose have been associated with increased risk
of atrial fibrillation in a number of epidemiological studies, however, the findings have not …

Background The aims of this study were to:(i) report the baseline characteristics of patients
enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA …

Aims Whether prevalence and mortality of patients with heart failure with preserved or mid-
range (40–49%) ejection fraction (HFpEF and HFmREF) are similar to those of heart failure …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Background: Asian American individuals comprise the fastest-growing race and ethnic
group in the United States. Certain subgroups may be at disproportionately high …

Background Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of …

Background Physicians' adherence to guideline‐recommended therapy is associated with
short‐term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF) …

Objectives: The purpose of this study was to compare outcomes (and the effect of
sacubitril/valsartan) according to etiology in the PARADIGM-HF (Prospective comparison of …

Background Heart failure is a global public health problem, affecting a large number of
individuals from low-income and middle-income countries. REPORT-HF is, to our …